Kristin Sanford

Lawdragon named Kristin to its 2026 “500 Leading Global Antitrust & Competition Lawyers” list. In 2024 and 2025, Lawdragon named Kristin to its “X – The Next Generation” list.

Prior to joining Weil, Kristin interned at the US Federal Trade Commission in a commissioner’s office. Kristin is a member of the American Bar Association’s Section of Antitrust Law, served as a Young Lawyer Representative for the Section’s Task Force on International Divergence of Dominance Standards (2017 – 2019), and has been a contributing editor to the ABA’s Annual Review of Antitrust Law Developments.

Kristin obtained her J.D. from the Georgetown University Law Center where she served as a Law Fellow in the Legal Research and Writing Department. She earned her B.A., with distinction, from Duke University. Prior to law school, Kristin was a revenue management analyst at American Airlines.

Key Representations

• The Home Depot, Inc. in its $4.3 billion acquisition of GMS Inc.
• Cedar Fair, L.P. in its $8 billion merger with Six Flags Entertainment..
• Johnson & Johnson in numerous transactions, including:
• The $3.05B acquisition of Halda Therapeutics OpCo, Inc.
• The acquisition of medical device maker V-Wave for up to $1.7 billion
• The $13.1B acquisition of Shockwave Medical
• The $275M+ sale of its Acclarent ENT surgery division to Integra
• The ~$16.6 billion acquisition of heart pump maker Abiomed Inc.
• The acquisition of orthopedic company CrossRoads Extremity Systems
• The ~$1.045 billion divestiture of the Codman Neurosurgery business to Integra LifeSciences Holding Corporate
• Providence Equity Partners and its portfolio company 365 Retail Markets in the acquisition of Cantaloupe, Inc. for approximately $848 million.
• NanoString Technologies, Inc. in a patent and antitrust litigation against 10x Genomics, Inc. and Harvard College in the District of Delaware.
• Abbott Laboratories in its $850 million acquisition of Cardiovascular Systems, Inc., a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
• C&S Wholesale Grocers in connection with the Federal Trade Commission’s study under Section 6(b) of the FTC Act regarding the competitive impact of supply chain disruptions in consumer goods.
• Meta (f/k/a Facebook) in its acquisition of Kustomer, a customer relationship management company.
• Fidelity National Financial, Inc. in New York Attorney General Letitia James’ investigation into possible violations of New York state antitrust laws and Section 1 of the Sherman Act. The investigation was part of the Attorney General’s broader review of alleged “no-poach” agreements between competitors in the title insurance industry.
• A leading television broadcaster in an investigation by the U.S. Department of Justice alleging that broadcasters unlawfully shared revenue pacing information and negotiation of a consent decree to resolve and settle the DOJ Antitrust Division’s claims.
• Maxim Integrated Products, Inc., a semiconductor manufacturer, in its over $20 billion sale to Analog Devices, Inc.
• BASF in its $11B acquisition of seed and herbicide businesses and assets pursuant to a DOJ antitrust consent decree in connection with Bayer’s acquisition of Monsanto. At the time, BASF’s acquisition was the largest negotiated merger divestiture in the history of US antitrust enforcement.
• Abbott Laboratories, a global, broad-based health care company, in its acquisition of Alere Inc., a global leader in point of care diagnostics, in a deal valued at approximately $5.3 billion, successfully securing clearance from the U.S. Federal Trade Commission.
• The Sherwin-Williams Company in its $11.3 billion acquisition of The Valspar Corporation, a leading manufacturer of paint and coatings.
• The Great Atlantic & Pacific Tea Company, Inc. (A&P) in its chapter 11 case. As part of the chapter 11 plan, A&P sought to sell 120 stores to supermarket competitors, including Albertsons, Royal Ahold, and Key Food Stores. Weil secured antitrust clearance from the FTC for the sale of A&P’s stores, relying in part on the rarely-successful failing firm defense.
• Iron Mountain in its $2.6 billion acquisition of Recall Holdings, successfully securing regulatory approval from the U.S. Department of Justice.
• AbbVie, a global biopharmaceutical company, in its acquisition of Pharmacyclics, Inc., a transaction valued at $21 billion and which closed without the FTC issuing a Second Request.